KeyBanc Maintains Recursion Pharmaceuticals(RXRX.US) With Buy Rating, Maintains Target Price $12

Moomoo NewsOct 2 18:32 ET · Ratings

Recursion Pharmaceuticals' Groundbreaking Cancer Drug Enters Clinical Trials

TipRanksOct 2 08:29 ET

Express News | Recursion Pharmaceuticals Shares up 2.8% Premarket on Getting US FDA Clearance for Early-Stage Cancer Drug Trial

ReutersOct 2 08:14 ET

Express News | Recursion Pharmaceuticals Inc - to Initiate Phase 1/2 Dosing of REC-1245 in Q4 2024

ReutersOct 2 08:00 ET

Express News | Recursion Announces FDA Clearance of Investigational New Drug Application for REC-1245, a Potential First-in-Class Rbm39 Degrader for Biomarker-Enriched Solid Tumors and Lymphoma

ReutersOct 2 08:00 ET

Recursion Announces FDA Clearance of Investigational New Drug Application for REC-1245, a Potential First-In-Class RBM39 Degrader for Biomarker-Enriched Solid Tumors and Lymphoma

GlobeNewswireOct 2 08:00 ET